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Introduction
Localized thrombus formation as a consequence of cardi-
ovascular disorders can lead to acute arterial or venous
occlusions. Heparin is the standard medication in emer-
gency treatment of occlusive events, but optimization of
antithrombotic mediation of acute thrombi remains a sig-
nificant research challenge.
Methods
Perfluorocarbon (PFC) nanoparticles (NPs) were func-
tionalized via covalent attachment of the irreversible
thrombin inhibitor, PPACK (Phe(D)-Pro-Arg-Chlo-
romethylketone). Particle-PPACK coupling was verified
through zeta potential measurement and HPLC quantifi-
cation. Inhibition of thrombin cleavage of Tosyl-Gly-Pro-
Arg-4 nitranilide acetate was assessed via optical assay to
verify that PPACK activity against thrombin and selectivity
for thrombin over plasmin was not diminished on attach-
ment to the particles. PPACK NPs (n = 7), PPACK (n = 4),
heparin (n = 4), non-functionalized NPs (n = 7), and
saline (n = 7) were used to treat C57BL6 mice immedi-
ately following laser injury of the carotid artery. Time to
thrombotic occlusion of the injured artery was assessed
via Doppler flow measurement. For selected mice receiv-
ing NPs, particle retention in extracted carotid arteries was
assessed via 19F MRS/MRI at 11.7 T.
Results
PPACK activity against and specificity for thrombin was
verified before and after coupling to PFC NPs. In our
mouse injury model, PPACK and non-functionalized NPs
failed to significantly delay time to occlusion of the
carotid artery. Heparin delayed occlusion to a degree pre-
dicted by previously published data. PPACK NPs signifi-
cantly outperformed both heparin (p = .001) and PPACK
(p = .0006) in delaying occlusion of the carotid artery
(Figure 1). Quantitative 19F MRS indicated the presence of
more PFC NPs in occluded arteries of animals treated with
PPACK NPs (Figure 2) than in injured arteries of mice
treated with non-functionalized NPs. Uninjured arteries
from the same animals produced no 19F signal.
Conclusion
In our model, PPACK-functionalized PFC NPs surpassed
heparin in treatment of acute thrombosis. The particles
take advantage of PPACK's high affinity and specificity for
thrombin while utilizing the vascular confinement and
long circulating half-life of the PFC NPs. 19F MRS and MRI
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indicate that PPACK NPs are retained in forming clots. As
a potent antithrombotic that can be traced with 19F MRS
and MRI, PPACK NPs have great therapeutic potential.
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